Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib - Pfizer

Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Tofacitinib XR; Xeljanz; Xeljanz XR

Latest Information Update: 22 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Oregon Health & Science University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase III Glioblastoma
  • Phase II COVID-19 pneumonia
  • Phase I/II Cutaneous lupus erythematosus; Diffuse scleroderma; Systemic lupus erythematosus
  • Preregistration Submission Withdrawal Plaque psoriasis
  • No development reported Dermatomyositis; Granuloma annulare; Pulmonary sarcoidosis; Sarcoidosis
  • Discontinued Asthma; Atopic dermatitis; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 07 Dec 2023 Pfizer completes the phase III trial for Ulcerative-colitis in USA (PO) (NCT04505410)
  • 14 Oct 2023 Pooled safety data of Clostridium difficile infection in ulcerative colitis from phase II, phase III and phase IIIb/IV trials presented at the 31st United European Gastroenterology Week (UEGW-2023)
  • 31 May 2023 Pharmacodynamics data from a phase III trial in Juvenile rheumatoid arthritis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top